Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linnéa Olofsson to the Company's board of directors (the "Board").
Mr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus on their business.
The Company is pleased to appoint Dr. Olofsson to the Board, effective June 1, 2022. Dr. Olofsson will also be a member of the Board's audit committee and the corporate governance and nominating committee.
Dr. Olofsson is a business entrepreneur with a background in development, clinical trials, and commercialization.
PreveCeutical has retained the services of Empire Relations Group effective June 1, 2022, for three months, at a fee of US$2,500 per month, to assist with investor awareness.
Stephen Van Deventer, PreveCeutical's Chief Executive Officer, commented, "We thank Mr. Anderson and Mr. Lotz for their contribution to the Company and wish them all the best. We are very pleased to have Dr. Olofsson join the Board. Dr. Olofsson's background, skillset, and experience will be very valuable to the Company."
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@preveceutical.com
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors, including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125651
The Dow Jones rallied amid encouraging inflation data. Tesla stock jumped even as CEO Elon Musk issued a warning. Apple stock surged.
These rapidly growing stocks are begging to be bought following a more than 30% peak decline in the Nasdaq.
The stock market pulled back from the brink of a bear market as rate-hike expectations eased, at least for now. Here's what it will take to signal a bottom.
Markets are shaky. Your income stream doesn’t have to be.
The stock market ended its multiweek losing streak, and like a sports team that finally got a win, it’s worth celebrating. It just doesn’t mean the team—or this stock market—is any good. “Stocks finally enjoyed a strong bounce this week,” writes Canaccord Genuity analyst Martin Roberge.
The market is unstable. Your portfolio doesn’t need to be.
Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials – than penny stocks. These equities, priced below $5 per share, typically offer high upside potentials. Even a small gain in share price – just a few cents – quickly translates into a high yield return. Of course, the risk is real, too; not every penny stock is going to show th
Qualcomm CEO Cristiano Amon weighs in on the outlook for the semiconductor industry and his company's future.
These two fintechs are generating strong revenue growth, but have been caught up in the market swoon.
The stock market is a game of risk and calculation, and in recent months the risks are mounting. The first quarter of 2022 showed a net negative GDP growth rate, a contraction of 1.4%; another contraction in Q2 will indicate a recession. Wall Street’s experts are trying to look ahead, to see through the fog of uncertainty and get some feel for where things are going. Covering the market for Morgan Stanley, chief US equity strategist Michael Wilson believes that we’ll dodge the recession bullet –
Will we have enough to ‘live a simple life’ in retirement? Many other retirees wonder the same thing as you, and may be in similar financial circumstances where they’re able to pay the bills and have money saved in their retirement accounts. Your interest rate is fantastic, you’re capable of making the monthly payment from just your pension and Social Security without tapping into your 401(k) and you have so much of your home already paid off — all wins.
Julian Bridgen, co-founder and president of Macro Intelligence 2 Partners, joins Yahoo Finance Live to discuss this week's market action and whether or not it will carry over into next week, the Fed, and inflation.
The top-ranked companies on dividend payout ratios outperformed those stocks with less robust buyback activity—10.9% versus 9.3% on an annual basis over the 20-year period that concluded at the end of 2019.
As of 12:24 p.m. ET, Aurora shares were still down 38.8%. At the same time, Tilray (NASDAQ: TLRY) shares were down 3.6%, and Hexo (NASDAQ: HEXO) stock was down 5.3%. The plunge in Aurora shares comes as existing shareholders react to a new round of financing that the company said will bring $150 million to the company.
Ulta shares are up after its big Q1 earnings beat, Aurora Cannabis increased its finance deal to $150 million, and Blackberry stock is surging after news of its partnership with Google.
In this article, we will discuss some of the notable stocks analysts are upgrading today. To take a look at some more stocks that are being upgraded, go to Analysts Are Upgrading These 5 Stocks on Friday. The US market closed in the green for the first time in the last seven weeks as positive […]
Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Global Equity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. For the first quarter of 2022, Aristotle Capital’s Global Equity Composite posted a total U.S. dollar return of -9.19% gross of fees (-9.28% net of fees), compared to […]
Wood's flagship Ark Innovation ETF has fallen 52% this year as technology companies have tumbled.
It’s been a long slog this year for the plummeting stock market. Citigroup’s model that forecasts the chances that stocks will head into a bear market shows that the market looks like more of a buy right now.
A weekly look at the most important moves and news in crypto and what's on the horizon in digital assets.